Phase I Study of MT1011 Injection in Healthy Subjects | stella

Learn Data Labs For Researchers Find trials matched to me

Learn Data Labs For Researchers Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Phase I Study of MT1011 Injection in Healthy Subjects | stella

Back to Used in Patients Receiving Anticoagulant Therapy (e.g., Rivaroxaban or Apixaban, Inhibitors of Coagulation Factor Xa) Who Require Reversal of Anticoagulation trials

Recruiting

Plain-English translation of NCT07024160 on ClinicalTrials.gov ↗ · Source last updated July 2025 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(1 site)

China

Beijing Shijitan Hospital, Capital Medical University, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing

Sponsor

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Enrollment target

~40 participants

Started

June 2025

Primary completion

April 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 45 Years

View full record on ClinicalTrials.gov

Last updated on clinicaltrials.gov in July 2025.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Xiao Hua Hao, Ph.D. in Medicine

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.